We have proved that targeting RFWD2 potentially overcomes BTZ resistance in vitro. To put forward our findings into in vivo study, we adopted paired 8226 WT and BTZ-resistant cells with RFWD2 KD in MM xenograft model. The gene discussed is CASC3; the disease is Miyoshi myopathy.